Business
Collaboration with global pharmaceutical partner
Collaboration with global pharmaceutical partner.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\nArecor Therapeutics plc\n(\"Arecor\" or the \"Company\")\n \nARECOR ENTERS COLLABORATION WITH MAJOR GLOBAL PHARMACEUTICAL PARTNER\n \n- Collaboration will leverage ArestatTM to develop a novel formulation of partner's proprietary product with enhanced properties\n- Work will be fully funded by partner\n \nCambridge, UK, 26 March 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has signed a formulation study agreement with a major global pharmaceutical partner.\n \nUnder the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a novel formulation of the partner's proprietary product with enhanced properties. The partner company will fully fund the formulation work with the potential for future license opportunities to follow.\n \nSarah Howell, Chief Executive Officer of Arecor, said: \"Arecor continues to partner with the world's leading pharmaceutical companies, which is testament to our leadership position in the field of drug delivery and formulation innovation and further validates the potential of our proprietary technology platform, Arestat™ to enable enhanced formulations of partners' proprietary products which would otherwise be unachievable.\"\n \nThis announcement contains inside information for the purposes of the retained UK version of the\nEU Market Abuse Regulation (EU) 596/2014 (\"UK MAR\").\n \n \nFor more information, please contact:\n \n\n\n\n\nArecor Therapeutics plc\n\n\nwww.arecor.com\n\n\n\n\nDr Sarah Howell, Chief Executive Officer\n\n\nTel: +44 (0) 1223 426060\nEmail: [email protected]\n\n\n\n\nDavid Ellam, Chief Financial Officer\n\n\nTel: +44 (0) 1223 426060\nEmail: [email protected] \n\n\n\n\n\n\n\n\n\n\n\n\nSinger Capital Markets Advisory LLP (NOMAD and Broker)\n\n\n\n\n\n\n\nPhil Davies, Sam Butcher\n\n\nTel: +44 (0) 20 7496 3000\n\n\n\n\n \n\n\n\n\n\n\n\nICR Healthcare\n\n\n\n\n\n\n\nChris Gardner, David Daley, Lindsey Neville\n\n\nTel: +44 (0) 20 3709 5700\nEmail: [email protected] \n\n\n\n\n \n\n\n\n\n\n\n\n \nNotes to Editors\n \nAbout Arecor\nArecor Therapeutics plc is a globally focused bi...